From January 1982 to May 2000, 17 infections caused by Burkholderia pseudomallei were diagnosed in 15 patients in Taiwan; almost all the infections were diagnosed from 1994 to May 2000. Of the 15 patients, 9 (60%) had underlying diseases, and 10 (67%) had bacteremic pneumonia. Thirteen (76%) episodes of infection were considered indigenous. Four patients died of melioidosis. Seventeen B. pseudomallei isolates, recovered from eight patients from November 1996 to May 2000, were analyzed to determine their in vitro susceptibilities to 14 antimicrobial agents, cellular fatty acid and biochemical reaction profiles, and randomly amplified polymorphic DNA patterns. Eight strains (highly related isolates) were identified. All isolates were arabinose nonassimilators and were susceptible to amoxicillin-clavulanate, piperacillintazobactam, imipenem, and meropenem. No spread of the strain was documented.
Research
Bacterial inocula were prepared by suspending the freshly grown bacteria in sterile normal saline and adjusted to a 0. 5 McFarland standard. Mueller-Hinton agar (BBL Microbiology Systems) was used for susceptibility testing. With a Steers replicator, an organism density of 10 4 CFU/spot was inoculated onto the appropriate plate with various concentrations of antimicrobial agents. Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were included as control strains. Antibiotypes were considered identical if all MICs tested were identical or within a twofold dilution discrepancy (22) .
Cellular Fatty Acid Chromatogram and Biotypes
Biotypes of these isolates were identified according to the reaction profiles obtained by API 20NE. Arabinose utilization was determined by growth on minimal salt agar containing L-arabinose (0.2%) (9) . Fatty acid methyl esters (FAMEs) of these isolates were analyzed by gas-liquid chromatography using a Hewlett-Packard 5890A (Hewlett-Packard; Avondale, PA) as described previously (22) . The software library used to identify the B. pseudomallei was TSA, version 3.9 (Microbial ID Inc., Newark, DE).
Strain Typing
Extraction of genomic DNA and polymerase chain reaction (PCR) for determining random amplified polymorphic DNA (RAPD) patterns generated by arbitrarily primed PCR of the 17 isolates of B. pseudomallei were performed as previously described (22) . Three oligonucleotide primers used were: M13 (5'-TTATGTAAAACGACGGCCAG-3' (Gibco BRL products, Gaithersburg, MD), ERIC1 (5'-GTGAATCCCCAG-GAGCTTACAT-3' (Gibco Bethesda Research Laboratories Products), and OPH-03 (5'-AGACGTCCAC-3') (Operon Technologies, Inc., Alameda, CA). To interpret RAPD patterns, both faint and intense bands were included (22) . The entire procedure, from bacterial growth to interpretation of RAPD pattern, was repeated three times for each isolate to confirm results. Patterns were considered identical only if they differed by no more than one band. Isolates were defined as being of the same strain (highly related isolates) if they had identical antibiotypes, biotypes, and RAPD patterns.
Results

Clinical Characteristics of Patients
From January 1982 to May 2000, 17 episodes of infection caused by B. pseudomallei were diagnosed in 15 patients in Taiwan. All but one episode occurred between 1994 and 2000 ( Figure 1 ; Table 1 ), indicating that cases have increased substantially in recent years. In these 15 patients, 13 were male; mean age was 64 years (range, 40 to 76 years). Patient 1 acquired pneumonia secondary to his near drowning in the Philippines. Patient 4 had had a fever during his stay in mainland China. Patient 6 had fever and left upper abdominal pain on his arrival in Taiwan after a 4-day trip in Rangoon, Burma. Patient 8 had septicemic melioidosis 5 years after travel to Thailand. The 13 other episodes (76%) were considered indigenous. Of the 11 patients with indigenous melioidosis, occupation was known for 7 patients (patients 9 to 15); none were rice farmers. Of the 15 infected patients, 9 (60%) had underlying diseases (6 had diabetes mellitus, and 3 had chronic obstructive pulmonary disease), 12 patients (80%) had pneumonia (including 10 with bacteremia and 1 with concomitant peritonitis), 2 (13%) had soft-tissue abscess, and 1 (7%) had mycotic aneurysm. Two patients each had two episodes of infection, separated by 8 and 10 months, respectively. Four patients (27%) died of melioidosis. One patient (no. 15), who had pneumonia caused by an organism initially identified as P. aeruginosa and treated at another hospital with ceftazidime and amikacin for 1 month, died on the third day in our hospital of refractory pneumonia complicated by empyema and acute respiratory distress syndrome. Two sets of blood cultures collected upon admission grew B. pseudomallei. Susceptibility results by the routine disk susceptibility test showed the organism was resistant to ceftazidime and amikacin. MICs of the organism to ceftazidime and amikacin were 32 µg/mL and >256 µg/mL, respectively (Table 2) .
Bacterial Isolates and Biotypes
All B. pseudomallei isolates had characteristic colonial morphology on trypticase soy agar supplemented with 5% sheep blood (BBL Becton Dickinson, Microbiology, Cockeysville, MD), positive oxidase reaction, and resistance to colistin and gentamicin. Of the 17 isolates (from eight patients), two biochemical profiles based on the results of identification by the API 20NE system were 1156576 (biotype I; citrate negative) and 1156577 (biotype II; citrate positive). All isolates tested were Ara-. The probability of identification of each B. pseudomallei biochemical profiles was 99.9%.
All 17 isolates (from eight patients) studied had similar FAME profiles, and all had five major FAMEs (each presenting >3% of the total): 14:0 (tetradecanoic acid), 3-OH-14:0 (3-hydroxytetradecanoic acid), 16:0 (hexadecanoic acid), 17:0cyc (-cis-9, 10-methylenehexadecanoic acid), 2-OH-16:0 (2-hydroxyhexadecanoic acid), 3-OH-16:0 (3-hydroxyhexadecanoic acid), 18:1w7c (cis-11-octadecenoic acid), and 19:0cyc (-cis-11, 12-methyleneoctadecanoic acid). FAME profiles of these isolates were consistent with the identification of B. pseudomallei.
Antimicrobial Susceptibilities and Antibiotypes
MICs of 14 antimicrobial agents for the 17 isolates of B. pseudomallei were determined (Table 2) . When MIC breakpoints for susceptibility and resistance used for nonEnterobacteriaceae were applied to B. pseudomallei (21) , all isolates were susceptible to amoxicillin-clavulanate, 
RAPD Patterns and Identification
Eight RAPD patterns were identified by use of the three primers ( Figure 2 ). RAPD patterns of multiple isolates from the same patients were identical. The two isolates (recovered 10 months apart) from patient 10 belonged to strain 5; two of the three isolates (recovered 8 months apart) from patient 11 were also identical (strain 6; Table 3 ). Isolates recovered from different patients had distinct RAPD patterns. Most of these infections were indigenous. All strains, whether imported or indigenous, were genetically distinct. Different patients were infected with different strains, indicating that spread of strains (intercontinental or within this island), as with Penicillium marneffei (another emerging pathogen in Taiwan), did not occur (23) . Our data suggest that Taiwan should be considered a melioidosis-endemic area, in addition to China, Australia, and Southeast Asia.
Melioidosis has been called the great mimicker because of its protean clinical features (1, 7) . The most common clinical sign is an acute pulmonary infection (as in our study), though its chronic pulmonary form often resembles tuberculosis (3, 16) . When localized, melioidosis may cause abscess formation in skin, soft tissue, joints, and visceral organs (1) . Melioidosis can become a latent infection that later (as much as 26 years after initial exposure) reactivates into a full-blown illness (even with acute septicemia) (1, 12) . The content of Ara-B. pseudomallei in the soil of a geographic area has been documented to correlate directly with the incidence of melioidosis in that area (5, 6) . In our study, all but four patients had no prior exposure to well-known diseaseendemic areas. Therefore, the strains of B. pseudomallei they acquired might have originated in Taiwanese soil. Unlike other reports (24) , most (87%) of our patients were male. Also, all but one patient with indigenous infection were >65 years, and none were rice farmers or obviously had heavy exposure to soil. Environmental surveys for the presence of this organism in the soil of Taiwan, especially in rice fields, are ongoing; thus far, B. pseudomallei has been isolated from two soil samples (data not shown). Although Ara+ B. pseudomallei has been reported to cause severe infection (10), all isolates Table 3 for designation of isolates). Research causing melioidosis in our study were Ara-. Our findings support previous observations (1, 5, 6) . B. pseudomallei are frequently intrinsically resistant to many antibiotics, including aminoglycosides and first-or second-generation cephalosporins (25, 26) . Current recommendations for therapy of severe melioidosis include intravenous ceftazidime or imipenem for 10 days to 4 weeks (25, 26) , followed by maintenance therapy with oral amoxicillin-clavulanate or a combination of trimethoprimsulfamethoxazole and doxycycline for 10 to 18 weeks (27-31). Cefotaxime and ceftriaxone are both less active than ceftazidime against B. pseudomallei in vivo and in vitro (28) . However, the observation of ceftazidime resistance's emerging during treatment has been previously reported (30) . Its occurrence in our patient 15 might be related to the presence of an empyema. In areas in which melioidosis is endemic, empirical regimens that contain cefotaxime or ceftriaxone for the treatment of severe community-acquired pneumonia or septicemia may not be appropriate.
Some investigators suggest that melioidosis is a facultative intracellular infection (25) . The failure of betalactam antibiotics to penetrate intracellular sites and kill nonmultiplying dormant bacteria may explain the frequent relapses of melioidosis after treatment with these drugs (25) . On the other hand, relapse is documented to be less common (10% versus 30%) in patients who complete a full course of antibiotic treatment (32) . Our two patients who had recurrent infections both received oral ciprofloxacin for 2 or 8 weeks. Nearly all isolates had MICs ranging from 1 µg/mL to 4 µg/mL for the three newer fluoroquinolones tested. Further studies are needed to determine the clinical efficacy of these newer fluoroquinolones for treating melioidosis and their role in preventing future relapse.
Several molecular typing methods have been applied to B. pseudomallei to evaluate the strain relationship in isolates recovered from humans and environment (33) (34) (35) (36) (37) . Among these methods, RAPD typing has also been documented to be useful for analyzing isolates that cause recurrent infection or reinfection (35) . In our study, RAPD typing using three primers clearly demonstrated the genetic diversity of isolates from different patients (with either imported or indigenous infections). In addition, this method showed that multiple isolates from the same patient and isolates causing recurrent infections were genetically identical. The microbial identification system, based on cellular FAME analysis by use of gas chromatography, is an established method for identifying species of bacteria and fungi and showing clustering in bacterial and fungal strains (22, 23) . Although all our isolates of B. pseudomallei had identical FAME profiles, cluster analysis of these esters (data not shown) failed to provide acceptable discriminatory power for typing the isolates.
In conclusion, Taiwan should be included as an endemic area of melioidosis, and physicians managing patients in Taiwan should be alert to the possibility that this organism might cause community-acquired pneumonia and sepsis.
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